# US 2024/0200043 A1 · Transcription activator-like effectors fused to inteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0200043 A1
- Document ID: US20240200043A1
- Status: Published application
- Kind: A1
- Application number: 17/906,163
- Filed: 2022-07-07
- Published: 2024-06-20
- Earliest claimed: 2021-07-07
- Assignees: Calyxt, Inc.
- Applicants: Calyxt, Inc.
- Inventors: Robert W. Williams; Sara Wixon
- Web page: https://patentgrep.com/patent/US20240200043A1

## CPC

- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/102: {Mutagenizing nucleic acids}
- C12N 15/62: DNA sequences coding for fusion proteins
- C12N 15/902: {using homologous recombination}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Embodiments of the present disclosure are directed to a plurality of nucleotide sequences encoding a first intein fused to at least a portion of a first transcription activator-like effector (TALE), a second nucleotide sequence encoding the first intein fused to at least a portion of a second TALE, and a third nucleotide sequence encoding a second intein fused to at least a portion of a rare-cutting nuclease.

## Claims

### Claim 1

A plurality of nucleotide sequences, comprising:
a first nucleotide sequence encoding a first of a first intein fused to at least a portion of a first transcription activator-like effector (TALE);
a second nucleotide sequence encoding a second of the first intein fused to at least a portion of a second TALE; and
a third nucleotide sequence encoding a second intein fused to at least a portion of a rare-cutting nuclease.

### Claim 2 (depends on 1)

The plurality of nucleotide sequences of claim 1, wherein:
the first nucleotide sequence encodes the first of the first intein fused to the first TALE and the second nucleotide sequence encodes the second of the first intein fused to the second TALE; and
the third nucleotide sequence encodes the second intein fused to the rare-cutting nuclease.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The plurality of nucleotide sequences of claim 1, wherein:
the first nucleotide sequence encodes the first of the first intein fused to a first portion of the rare-cutting nuclease and the first TALE, and the second nucleotide sequence encodes the second of the first intein fused to the first portion of the rare-cutting nuclease and the second TALE; and
the third nucleotide sequence encodes the second intein fused to a second portion of the rare-cutting nuclease, wherein the first portion and the second portion of the rare-cutting nuclease form the rare-cutting nuclease.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The plurality of nucleotide sequences of claim 1, wherein the plurality of nucleotide sequences each include a separate vector or are on a single expression construct.

### Claim 7 (depends on 1)

The plurality of nucleotide sequences of claim 1, wherein the first of the first intein and the second intein are configured to self-splice when in contact and, in response, to form a first half transcription activator-like effector nuclease (TALEN) including the first TALE bound to the rare-cutting nuclease.

### Claim 8 (depends on 7)

The plurality of nucleotide sequences of claim 7, wherein the second of the first intein and the second intein are configured to self-splice when in contact and, in response, to form a second half TALEN including the second TALE bound to the rare-cutting nuclease.

### Claim 9 (depends on 1)

The plurality of nucleotide sequences of claim 1, wherein each of the first of the first intein, the second of the first intein, and the second intein are configured to self-splice when in contact and to form spliced proteins including the first of the first intein bound to one of the second intein and the second of the first intein bound to another of the second intein.

### Claim 10

(canceled)

### Claim 11

A method, comprising:
contacting a cell with:
a first nucleotide sequence encoding a first of a first intein fused to at least a portion of a first transcription activator-like effector (TALE);
a second nucleotide sequence encoding a second of the first intein fused to at least a portion of a second TALE; and
a third nucleotide sequence encoding a second intein fused to at least a portion of a rare-cutting nuclease; and
in response to contacting the cell, splicing the first TALE, the second TALE, and the rare-cutting nuclease by the first of the first intein and the second of the first intein to ones of the second intein to form:
a first half transcription activator-like effector nuclease (TALEN) including the first TALE and the rare-cutting nuclease; and
a second half TALEN including the second TALE and the rare-cutting nuclease.

### Claim 12 (depends on 11)

The method of claim 11, further including translating the first nucleotide sequence, the second nucleotide sequence, and the third nucleotide sequence to form the first of the first intein fused to the first TALE, the second of the first intein fused to the second TALE, and the second intein fused to the rare-cutting nuclease.

### Claim 13 (depends on 11)

The method of claim 11, further including transforming the cell using the first half TALEN and the second half TALEN.

### Claim 14 (depends on 11)

The method of claim 11, wherein the first nucleotide sequence encodes an N-terminal intein fused to a C-terminal of the first TALE, the second nucleotide sequence encodes the N-terminal intein fused to a C-terminal of the second TALE, and the third nucleotide sequence encodes a C-terminal intein fused to an N-terminal of the rare-cutting nuclease or the C-terminal intein fused between portions of the rare-cutting nuclease.

### Claim 15 (depends on 11)

The method of claim 11, wherein the first nucleotide sequence encodes a C-terminal intein fused to an N-terminal of the first TALE, the second nucleotide sequence encodes the C-terminal intein fused to an N-terminal of the second TALE, and the third nucleotide sequence encodes an N-terminal intein fused to a C-terminal of the rare-cutting nuclease or the N-terminal intein fused between portions of the rare-cutting nuclease.

### Claim 16 (depends on 11)

The method of claim 11, wherein splicing includes binding each of the first of the first intein and the second of the first intein to ones of the second intein to form:
a first intermediate including the first of the first intein bound to a first of the second intein, wherein the first of the first intein is fused to the first TALE and the first of the second intein is fused to the rare-cutting nuclease; and
a second intermediate including the second of the first intein bound to a second of the second intein, wherein the second of the first intein is fused to the second TALE and the second of the second intein is fused to the rare-cutting nuclease.

### Claim 17 (depends on 11)

The method of claim 11, wherein splicing includes:
binding each of the first of the first intein and the second of the first intein to ones of the second intein;
cutting splice sites associated with the first of the first intein, the second of the first intein, and the ones of the second intein; and
binding the first TALE to the rare-cutting nuclease and binding the second TALE to the rare-cutting nuclease to form the first half TALEN and the second half TALEN.

### Claim 18 (depends on 17)

The method of claim 17, wherein the splice sites are between:
the first of the first intein and the first TALE;
the second of the first intein and the second TALE; and
the second intein and the rare-cutting nuclease or portions thereof.

### Claim 19

An expression construct, comprising:
a first nucleotide sequence encoding a first of a first intein fused to at least a first transcription activator-like effector (TALE);
a second nucleotide sequence encoding a second of the first intein fused to at least a second TALE; and
a third nucleotide sequence encoding a second intein fused to at least a portion of a rare-cutting nuclease.

### Claim at position 20

-21. (canceled)

### Claim 22 (depends on 19)

The expression construct of claim 19, wherein in response to translation of the first nucleotide sequence, the second nucleotide sequence, and the third nucleotide sequence by a cell, the first of the first intein and the second of the first intein are configured to bind to ones of the second intein and self-splice to form:
a first half transcription activator-like effector nuclease (TALEN) including the first TALE bound to the rare-cutting nuclease;
a second half TALEN including the second TALE bound to the rare-cutting nuclease; and
spliced proteins including the first of the first intein bound to one of the second intein and the second of the first intein bound to another of the second intein.

### Claim 23 (depends on 19)

The expression construct of claim 19, wherein the first nucleotide sequence, the second nucleotide sequence, and the third nucleotide sequence include separate vectors or are on a single expression construct.

### Claim 24 (depends on 19)

The expression construct of claim 19, wherein:
the first TALE includes a first plurality of TALE repeat sequences that, in combination, bind to a first nucleotide sequence in a target DNA sequence; and
the second TALE includes a second plurality of TALE repeat sequences that, in combination, bind to a second nucleotide sequence in the target DNA sequence.

### Claim 25 (depends on 19)

The expression construct of claim 19, wherein each of the first nucleotide sequence, the second nucleotide sequence, and the third nucleotide sequence further encode a promoter and a terminator.

### Claim at position 25

26-28. (canceled)
